Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

SAN DIEGO and TORONTO, May 14, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806, its oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, will be presented in a poster presentation at the 25th Congress of the European Hematology Association, EHA25 Virtual Congress, taking place June 11-14, 2020.